PTC Therapeutics | PTCT - Selling And Administration Expenses


PTC Therapeutics reported $73.89M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amgen USD 1.58B 354M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
Daiichi Sankyo JPY 249.96B 21.73B Jun/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 1.45B 326M Mar/2026
Incyte USD 351.73M 23.64M Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Novartis USD 3.24B 101M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026
Xencor USD 82.12M 65.08M Mar/2026